X O Breakefield
Overview
Explore the profile of X O Breakefield including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
264
Citations
5624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu W, Hurley J, Roberts D, Chakrabortty S, Enderle D, Noerholm M, et al.
Ann Oncol
. 2021 Feb;
32(4):466-477.
PMID: 33548389
Liquid biopsy in cancer has gained momentum in clinical research and is experiencing a boom for a variety of applications. There are significant efforts to utilize liquid biopsies in cancer...
2.
Pintar J, Maxwell G, Breakefield X
Int J Dev Neurosci
. 2014 May;
1(1):49-57.
PMID: 24875606
Catecholamines and other biogenic amines may play a role in early embryogenesis in addition to functioning as neurotransmitters after neuronal differentiation. Regulation of amine levels is mediated by several different...
3.
Pike L, Tannous B, Deliolanis N, Hsich G, Morse D, Tung C, et al.
Gene Ther
. 2011 Sep;
18(12):1173-8.
PMID: 21900963
Adeno-associated virus (AAV)-mediated gene replacement for lysosomal disorders have been spurred by the ability of some serotypes to efficiently transduce neurons in the brain and by the ability of lysosomal...
4.
Isacson O, Frim D, Galpern W, Tatter S, Breakefield X, Schumacher J
Restor Neurol Neurosci
. 2011 May;
8(1):59-61.
PMID: 21551807
No abstract available.
5.
Smith F, Jacoby D, Breakefield X
Restor Neurol Neurosci
. 2011 May;
8(1):21-34.
PMID: 21551801
A number of virus vectors have been developed for gene delivery to the nervous system. Virus vectors still provide the most efficient means of gene delivery, and this is critical...
6.
Herrlinger U, Jacobs A, Aghi M, Schuback D, Breakefield X
Methods Mol Med
. 2011 Mar;
35:287-312.
PMID: 21390812
Gliomas account for about 60% of all primary CNS tumors; two-thirds of all gliomas comprise the most malignant form, glioblastoma multiforme, or glioma grade IV. Although much progress has been...
7.
Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, et al.
Cancer Gene Ther
. 2010 May;
17(9):655-63.
PMID: 20508670
Oncolytic herpes simplex virus (HSV) vectors have been used in early phase human clinical trials as a therapy for recurrent malignant glioblastoma. This treatment proved safe but limited improvements in...
8.
Prabhakar S, Brenner G, Sung B, Messerli S, Mao J, Sena-Esteves M, et al.
Cancer Gene Ther
. 2009 Oct;
17(4):266-74.
PMID: 19834516
Schwannomas are benign tumors forming along peripheral nerves that can cause deafness, pain and paralysis. Current treatment involves surgical resection, which can damage associated nerves. To achieve tumor regression without...
9.
Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield X, et al.
Br J Cancer
. 2009 Apr;
100(10):1603-7.
PMID: 19401683
Herein, we describe a novel approach in the search for prostate cancer biomarkers, which relies on the transcriptome within tumour exosomes. As a proof-of-concept, we show the presence of two...
10.
Jeong K, Bakowska J, Song I, Fu N, Breakefield X, Kaiser U
Gene Ther
. 2007 May;
14(14):1092-101.
PMID: 17476303
One of the challenges of gene targeting is to achieve regulated transgene expression in specific target cells. The hypogonadal (hpg) mice are genetically deficient in hypothalamic gonadotropin-releasing hormone (GnRH) production...